Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

Ezra Cohen, MD
Published: Thursday, Jul 27, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Immunotherapy is currently used as standard of care for patients who have either recurred after curative intent therapy within 6 months of completion, or in patients who have had progressed on first-line platinum-containing therapy.



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Immunotherapy is currently used as standard of care for patients who have either recurred after curative intent therapy within 6 months of completion, or in patients who have had progressed on first-line platinum-containing therapy.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x